Penciclovir /g

Phase 3Small molecule

EEMS

Penciclovir /g is one of 11 small molecule programs targeting Herpes Labialis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Herpes LabialisActive, not recruiting

Herpes LabialisPhase 3

Active, not recruiting

Competition

Competitive Landscape

20 competitors in Herpes Labialis

#DrugCompanyPhaseTrials

Famvir

Novartis

Approved

2 2

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Zovirax

Valtrex

GGlaxo Dba Glaxosmithkline

Glutamine

1 6

NB-001

NNobias Therapeutics, Inc.

Phase 3

3 7

Penciclovir /g

EEMS

Phase 3

1 8

Abreva

HHALEON

Phase 2

2 9

Squaric Acid Dibutyl Ester

SSquarex, LLC

Phase 2

1 10

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Herpes Labialis1 trial

Non-inferiority Comparison of Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis

Completed·EEMS·Phase 3·NCT01257074·76 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Penciclovir /g. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Penciclovir /g compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Penciclovir /g. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EMS company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEMS

Penciclovir /g

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Herpes Labialis1 trial

References

Drug Info

Quick Facts

Related News